Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?

doi:10.3748/wjg.v27.i40.6737

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 40

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6537)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

493

WORD

113

HTML

3481

Figures (1-2)

435

Tables (1-1)

534

Sum=5056

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

487

Download

994

Sum=1481

Oct 28, 2021 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Frontier

World J Gastroenterol. Oct 28, 2021; 27(40): 6737-6749
Published online Oct 28, 2021. doi: 10.3748/wjg.v27.i40.6737

Open in New Tab Full Size Figure Download Figure

Figure 1 Factors involved in increasing or decreasing hepatocellular carcinoma risk, either before or after sustained virologic response. EV: Esophageal varices; VB: Variceal bleeding; ACLF: Acute on chronic liver failure; PH: Portal hypertension; SVR: Sustained virologic response; HCC: Hepatocellular carcinoma; MAFLD: Metabolic associated fatty liver disease.

Open in New Tab Full Size Figure Download Figure

Figure 2 Surveillance hepatocellular carcinoma algorithm proposed. ¹Most likely, annual incidence < 0.5% per year. FIB-4: Fibrosis 4; LSM: Liver stiffness measurement; TE: Transient elastography; PHT: Portal hypertension; DM: Diabetes mellitus; MS: Metabolic syndrome; MAFLD: Metabolic associated fatty liver disease.

Citation: Ahumada A, Rayón L, Usón C, Bañares R, Alonso Lopez S. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long? World J Gastroenterol 2021; 27(40): 6737-6749
URL: https://www.wjgnet.com/1007-9327/full/v27/i40/6737.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i40.6737